Tirzepatide First 3 Months: What Houston Patients Experience Week by Week

Tirzepatide begins at 2.5 mg weekly — a low starting dose designed to allow the body to adjust before moving to therapeutic levels. Most Houston patients report minimal appetite suppression at this dose, which can feel discouraging if they were expecting immediate results. Nausea at 2.5 mg is mild for most patients. The most important task in weeks 1–4 is building the injection routine: choosing a consistent injection day, learning proper subcutaneous technique (abdomen, thigh, or upper arm are the standard sites), and storing the pen correctly (refrigerated at 36–46°F — critical in Houston's heat). Weight loss in the first month is typically modest: 2–5 lbs for most patients. Don't judge the medication by week 4.

At week 5, most Houston clinic protocols advance tirzepatide to 5 mg weekly. This is the dose where GI side effects — nausea, bloating, constipation, and occasionally vomiting — are most likely to appear or intensify. The 5 mg dose is where dropout rates are highest: patients who aren't prepared for the side effects or don't have strategies for managing them often stop at this point. Key management strategies Houston physicians recommend: eat smaller meals (the medication slows gastric emptying — a large meal is much harder to tolerate), avoid high-fat and spicy foods during the first few weeks at each new dose, eat slowly, and stay well-hydrated. For most patients, GI effects at 5 mg are manageable and resolve within 2–3 weeks as the body adapts.

By week 9–10, most Houston clinic protocols move to 7.5 mg, and this is typically when patients first notice dramatic appetite suppression. Many describe going from eating unconsciously to genuinely not feeling hungry — sometimes forgetting to eat entirely. Weight loss accelerates noticeably for most patients in weeks 9–12: 1–3 lbs/week is common at this stage, depending on starting weight and dietary changes. The challenge here is eating enough protein and maintaining nutritional balance despite severely reduced appetite. Houston providers consistently advise patients at this stage to track protein specifically (target 0.7–1.0g per pound of goal body weight), even when not hungry. Skimping on protein at 7.5 mg and above is the most common nutritional mistake in tirzepatide programs.

By the end of the first 3 months on tirzepatide (through the 7.5 mg phase), Houston patients in physician-supervised programs typically lose 8–15% of starting body weight, though individual results vary based on adherence, starting weight, diet, and exercise. SURMOUNT-1 trial data showed roughly 10–12% mean weight loss at the 12-week mark. Patients who combine tirzepatide with consistent resistance training and protein-focused eating tend to lose more total body fat and retain more muscle mass than those who rely on the medication alone. This 3-month mark is also when Houston providers typically evaluate whether to continue at 7.5 mg or advance to 10 mg, based on how well the current dose is tolerated.

Houston's climate creates a practical challenge for tirzepatide patients: the medication pens must be refrigerated at 36–46°F and should never be left in a car, where interior temperatures can exceed 130°F in summer within minutes. Exposure to heat degrades the medication, making it less effective. Patients who travel to outdoor Houston events should carry the pen in an insulated medical cooler. A secondary concern is hydration — GI side effects on tirzepatide increase dehydration risk, and Houston's heat amplifies this. Houston providers typically advise patients to drink 8–10 cups of water daily during the first three months, especially during the warm months.

Tirzepatide has a dual mechanism — it activates both GLP-1 and GIP receptors — while semaglutide only activates GLP-1. In practice, the first 3 months feel similar for most patients, with two notable differences: tirzepatide tends to produce more pronounced appetite suppression at equivalent stages of dose escalation, and the GI side effects, particularly nausea and constipation, can be more intense during the 5 mg and 7.5 mg phases. Patients who have used semaglutide previously and switched to tirzepatide often report stronger appetite suppression on tirzepatide but a similar side effect profile. Clinical outcomes clearly favor tirzepatide for total weight loss over a full treatment course.

If you miss a tirzepatide dose by 1–3 days, inject as soon as you remember and then resume your normal weekly schedule. If more than 4 days have passed since the missed dose, skip it and continue with your next scheduled injection. Missing doses during the first 3 months — particularly during the dose-escalation phase — can disrupt your body's adaptation to the medication and increase the likelihood of side effects returning when you resume. Houston providers typically advise setting a weekly phone reminder for injection day and keeping backup storage instructions handy for travel. Never inject two doses in the same week to compensate for a missed dose.